Skip to main content

A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMABAND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA

Clinical Trial Grant
Duke Scholars

Awarded By

Regeneron Pharmaceuticals, Inc.

Start Date

June 5, 2025

End Date

June 12, 2030
 

Awarded By

Regeneron Pharmaceuticals, Inc.

Start Date

June 5, 2025

End Date

June 12, 2030